Wound Management Technologies, Inc.: CellerateRX(R) Effectively Manages Diabetic Ulcers

FORT WORTH, Texas, Nov. 10, 2010 /PRNewswire/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a leader in advanced wound care solutions, is meeting the challenge of a rise in type 2 diabetes in the US, as chronicled by a new report by the Center for Disease Control (CDC). The report published in the October 22, 2010 journal Population Health Metrics recommends that proper diet and physical activity can prevent type 2 diabetes and reduce its complications, among the most severe of which are diabetic ulcers and amputations. Wound Management, exclusive worldwide licensee and distributor of CellerateRX® wound care powder and gel, further recommends that existing diabetic patients who suffer from moderate to heavily exudative wounds should ask their doctor whether CellerateRX® may be an effective treatment for them. CellerateRX® is the only activated Type 1 collagen-based product reimbursed by Medicare and has been shown to effectively manage diabetic ulcers.

Diabetes is $174B Cost to US Economy

The current CDC report states that the total costs of diabetes are currently estimated to be $174 billion annually, including $116 billion in direct medical costs. If CDC recommendations are not widely adopted and current trends of obesity continue, diabetes is projected to affect between 1 in 3 to 1 in 5 Americans by 2050.

Untreated Diabetic Wounds Can Lead to Amputations

Diabetics are at high-risk for wound infection due to their varying blood sugar levels, circulation changes, and impaired local immune defenses, all of which predispose them to delayed healing and infection. Diabetic wound complications are the most common cause of non-traumatic lower extremity amputations in the industrialized world. According to the Centers for Disease Control (CDC), sixty percent of lower limb amputations are associated with diabetes. "Between 15-25% of people with diabetes will develop foot and leg ulcers at some point (1) in their lives," said Cathy Bradshaw, President of Wound Care Innovations, LLC.

CellerateRX® Effectively Manages Diabetic Ulcers

Wound Care Innovations' advanced wound care collagen product, CellerateRX®, has been shown in multiple clinical applications and settings to be extremely effective in managing these challenging diabetic wounds. In one study, wounds where CellerateRX® was applied were healed within five (5) weeks with a once or twice per week application. This is in contrast to the control wounds that were only approximately 80% healed at twelve (12) weeks.(2) "The ideal product to effectively manage these difficult wounds provides for quality outcomes in a cost effective manner," said Dr. Larry Baratta, VP of Medical Affairs. "CellerateRX® has been shown to do just this." Jane Fore MD, FAPWCA, FACCWS, Medical Director, Tri-State Wound Care and Hyperbaric Center states, "CellerateRX is the standard of care in my clinic. This product is compatible with other wound care products and gives the wound environment the basic building blocks for growth, and contributes an essential part of the wound matrix that supports the migration of cells to healing tissues. Wound healing deficiencies are more common in diabetics and CellerateRX® collagen provides an essential factor that aids in overcoming challenges in healing diabetic wounds."

CellerateRX® Activated Collagen is the Differentiator

CellerateRX's activated collagen (approximately 1/100th the size of native collagen) delivers the essential benefits of collagen to a wound immediately, where other forms of native, intact collagen in commercially available products require time for the body to prepare the collagen for use in the wound healing process. In people with compromised health or circulation, the difference in wound healing can be significant.

CellerateRX® is FDA cleared for all wound types except for 3rd degree burns and is available in both powder and gel form. In addition to being used in healthcare settings throughout the country, CellerateRX® is easily applied by patients by themselves at home. CellerateRX® is safe, non-toxic, and easy to use; in fact, the product can be purchased through Wound Care Innovations, LLC website at http://www.CellerateRX.com/pages/products.php

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc.'s primary focus is the distribution of its unique, patented collagen product, CellerateRX®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes. Over the past 2 years, Wound Management has focused on developing evidenced-based studies on CellerateRX® and gaining physician awareness by participation in key industry conferences. Now Wound Management is focused on expanding sales through partnerships and contracted independent representatives. Wound Management has other advanced biotech products in development, in addition to a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com and http://www.CellerateRX.com.

Safe Harbor Statement:

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com

SOURCE Wound Management Technologies, Inc.